- QIAGEN expands market for gold standard latent TB test to help developing countries fight TB
- WHO-endorsed test to support communities with the highest need
- First demonstration of QuantiFERON(R)-TB Access at the Union World meeting in India
HILDEN, Germany & GERMANTOWN, Md.–(BUSINESS WIRE)–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON(R)-TB Gold Plus (QFT(R)-Plus) has been added to the diagnostic catalog of the Stop TB Partnership’s Global Drug Facility (GDF), opening a new channel to reach countries with a high incidence of tuberculosis (TB), in particular areas where QIAGEN has no direct commercial presence.
The GDF is the largest provider to the public sector of quality-assured tuberculosis medicines, diagnostics and laboratory supplies. Operating a unique pooled procurement system, the GDF facilitates access and helps match demand for TB diagnostics and drugs with funding from donors, governments and non-governmental organizations.
The acceptance of QFT-Plus for the GDF catalog advances QIAGEN’s strategy to help expand screening with modern blood-based assays for latent TB infection in regions with a high disease burden but limited resources. In addition, QIAGEN is working with the World Health Organization (WHO), governments and NGOs (non-governmental organizations) in the global fight to eradicate TB. In its Global Tuberculosis Report 2019, the WHO endorsed QFT-Plus for diagnosis of latent TB infection as part of its new guidelines to target prevention in the goal to eradicate TB. QIAGEN is supporting QFT-Plus accessibility through GDF with additional training and educational programs.
For more information about QFT-Plus, please visit www.quantiferon.com.
Please find the full press release here.
Vice President Corporate Communications and Investor Relations
+49 2103 29 11711 and +1 240 686 2222
Associate Director Investor Relations
+49 2103 29 11457
Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
+49 2103 29 11826 and +1 240 686 7425